Agenus Inc. (AGEN) Stock: Seeing Gains In Today’s Session

0

Agenus Inc. (AGEN) is gaining in the market in today’s trading session. The stock, focused on the biotechnology sector, is currently priced at $2.60 after climbing 18.72% so far in today’s session. In terms of biotech companies, there are several factors that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines associated with AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 09:35AM Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
07:30AM Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
07:30AM Agenus Milestone Triggers $7.5M Payment
Aug-06-19 10:56AM Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast
Jul-26-19 11:04AM Is Agenus (NASDAQ:AGEN) Using Too Much Debt?

Nonetheless, any time investors are making a decision to invest, prospective investors should look into much more than news, especially in the highly speculative biotechnology space. Here’s what’s going on with Agenus Inc..

Recent Movement Out of AGEN

Although a move up on a single session, like the move that we’re seeing from Agenus Inc. might lead to excitement in some investors, a single session gain alone should not be the reason for a decision to, or not to, buy a company’s stock. It is generally important to take a look at trends for a period longer than a single trading session. In the case of AGEN, below are the trends that we’ve seen:

  • Weekly – Over the past 7 days, AGEN has seen a change in price that amounts to 5.69%.
  • Monthly – The ROI from Agenus Inc. in the last 30 days works out to -4.76%.
  • Past Quarter – Over the last quarter, the company has produced a return on investment of -9.72%
  • Bi-Annually – Throughout the past 6 months, we’ve seen a change that equates to -23.98% from the stock.
  • This Year So Far – Since the open of this year AGEN has produced a return of 9.24%.
  • Annually – Lastly, throughout the last full year, we’ve seen movement amounting to 51.16% out of AGEN. In this period, the stock has sold at a high price of -32.99% and a low price of 68.83%.

Key Ratios

Looking at a few key ratios having to do with a company can give investors a view of just how dangerous and/or potentially profitable a stock pick might be. Here are a few of the important ratios to consider when looking at AGEN.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it means that more investors have a belief that the value of the stock is headed for declines. Throughout the sector, biotech stocks can come with a higher short ratio. However, we tend to see a lot of short squeezes in the space. Nonetheless, in relation to Agenus Inc., it’s short ratio is 11.53.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts as they mature using quick assets or current assets. Because many biotech several companies are heavily reliant on the continuation of support from investors, the quick and current ratios can look damning. Nonetheless, several gems in the biotechnology space come with positive quick and current ratios. In terms of AGEN, the quick and current ratios come to 1.70 and 1.70 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets that are owned by the company. In this particular case, that ratio is -0.90.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the value of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to look into. In this case, the cash to share value ratio comes to 0.

How Analysts Feel About Agenus Inc.

Although it’s not a smart idea to unknowingly follow the opinions of analysts, it is a good idea to consider their thoughts when validating your own before making investment decisions in the biotechnology industry. Here are the recent moves that we’ve seen from analysts with regard to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Show Me The Big Money

One thing that I’ve come to understand in my short time on Earth is that smart investors tend to follow the moves made by big money players. In general, investors that are trying to play it relatively safe will follow moves made by institutional investors as well as insiders of the company. With that said, what does the big money picture look like in regard to AGEN? Here’s the scoop:

  • Institutional Investors – At the moment, institutional investors own 33.80% of Agenus Inc.. Nonetheless, it’s important to mention that the ownership held by institutions has seen a move in the amount of 0.98% throughout the past quarter.
  • Insider Moves – with regard to insiders, insiders of the company currently own 24.18% of the company. Their ownership of the company has seen a change of 0.00% throughout the last quarter.

What’s Going On With Share Counts?

Investors seem to be interested in the amounts of shares both outstanding and available. As far as Agenus Inc., currently there are 139.96M with a float of 102.14M. These numbers mean that of the total of 139.96M shares of AGEN that are out there today, 102.14M are available to be traded on the market.

I also find it important to pay attention to the short percent. After all, if a high portion of the float is shorted, the overall opinion in the market is that the company is going to take a dive. As far as AGEN, the percentage of the float that is shorted currently sits at 11.90%. Most investors would say that a concerning short percent of the float would be considered to be anything over 40%. In my research, I have found that a short ratio over 26% is probably going to be a play that comes with hefty risk.

Financial Performance

What have ween seen from AGEN in terms of financial results?Here’s the information:

  • Analyst Expectations – At the moment, Wall Street analysts expect that Agenus Inc. will come up with EPS coming to a total of -1.29, with -0.33 to be reported in the earnings announcement for the current quarter. Although this data is not earnings driven, because we are chatting on the topic of analysts, the stock is currently graded as a 1.30 on a scale from 1 to 5 where 1 is the poorest analyst rating and 5 is the best possible rating.
  • 5-Year Sales – Over the past half decade, Agenus Inc. has announced a movement in sales in the amount of 64.60%. Earnings through the last 5 years have generated a change of -5.30%.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is commonly represented in today’s society, AGEN has generated a change in earnings in the amount of 123.50%. The company has also seen movement with regard to revenue in the amount of 4783.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I have the ability to learn by myself. However, I was made by a human and human beings actually play a crucial part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here